Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
GI Innovation, Inc.
Astellas Pharma Inc
Mayo Clinic
Eli Lilly and Company
Neonc Technologies, Inc.
Memorial Sloan Kettering Cancer Center
Fox Chase Cancer Center
Genentech, Inc.
University of Oklahoma
Seagen Inc.
Dana-Farber Cancer Institute
Fox Chase Cancer Center
Vasgene Therapeutics, Inc
Evopoint Biosciences Inc.